##### Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



---

FORM 10-Q



---



|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------

For the quarterly period ending June 30, 2007

OR



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------

For the transition period from  to

Commission file number: 333-132913



---

MSC-Medical Services Company

(Exact name of registrant as specified in its charter)



---



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Florida                                                        |  | 59-2997634                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
|                                                               | 
|11764-1 Marco Beach Drive Jacksonville, FL                     |  | 32224                               
|(Address of principal executive offices)                       |  | (Zip Code)                          

(904) 646-0199

(Registrants telephone number, including area code)



---

The registrant has no securities registered pursuant to Sections 12(b) or 12(g). The registrant files periodic reports under the Securities Exchange Act
of 1934 solely to comply with requirements under that certain Indenture related to its Senior Secured Floating Rate Notes due 2011. The Indenture and form of note are filed with the Securities and Exchange Commission as part of the registrants
Registration Statement on Form S-4, amended as of May 17, 2006.



---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days.    Yes  x    No ̈

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of
accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act.

Large accelerated
filer ̈Accelerated filer ̈Non-accelerated filer x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ̈No  x

Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.



|                                        |  |                             
|--------------------------------------- |  | ----------------------------
|Class                                   |  | Outstanding at July 31, 2007
|Common Stock, $1.00 par value per share |  | 100 shares                  



---



---

##### Table of Contents

Table of Contents



|     |  |                                                                                                          |  |   
|---- |  | -------------------------------------------------------------------------------------------------------- |  | --
|Item |  |                                                                                                          |  |   
|     |  | Forward-Looking Statements                                                                               |  | 3 
|     |  |                                                                                                         
|     |  | Part IFinancial Information                                                                             |  |   
|     |  |                                                                                                         
|1.   |  | Financial Statements:                                                                                    |  |   
|     |  |                                                                                                         
|     |  | Condensed Balance Sheets As of June 30, 2007 (Unaudited) and December 31, 2006                           |  | 5 
|     |  | Condensed Statements of Operations (Unaudited) For the Three and Six Months Ended June 30, 2007 and 2006 |  | 7 
|     |  | Condensed Statements of Cash Flows (Unaudited) For the Six Months Ended June 30, 2007 and 2006           |  | 8 
|     |  | Notes to Unaudited Condensed Financial Statements                                                        |  | 9 
|     |  |                                                                                                         
|2.   |  | Managements Discussion and Analysis of Financial Condition and Results of Operations                    |  | 20
|     |  |                                                                                                         
|3.   |  | Quantitative and Qualitative Disclosures About Market Risk.                                              |  | 28
|     |  |                                                                                                         
|4T.  |  | Controls and Procedures                                                                                  |  | 28
|     |  |                                                                                                         
|     |  | Part IIOther Information                                                                                |  |   
|     |  |                                                                                                         
|1.   |  | Legal Proceedings                                                                                        |  | 29
|     |  |                                                                                                         
|1A.  |  | Risk Factors                                                                                             |  | 29
|     |  |                                                                                                         
|2.   |  | Unregistered Sales of Equity Securities and Use of Proceeds                                              |  | 29
|     |  |                                                                                                         
|3.   |  | Defaults Upon Senior Securities                                                                          |  | 29
|     |  |                                                                                                         
|4.   |  | Submission of Matters to a Vote of Security Holders                                                      |  | 29
|     |  |                                                                                                         
|5.   |  | Other Information                                                                                        |  | 29
|     |  |                                                                                                         
|6.   |  | Exhibits                                                                                                 |  | 29
|     |  |                                                                                                         
|     |  | Signatures                                                                                               |  | 30



2



---

##### Table of Contents

FORWARD-LOOKING STATEMENTS

Management may from time-to-time make written or oral forward-looking statements
with respect to the Companys annual or long-term goals, including statements contained in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K, and our Current Reports on Form 8-K filed with the Securities and Exchange
Commission (the SEC), and our press releases and other communications. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical earnings and those currently anticipated
or projected. Management cautions readers not to place undue reliance on any of the Companys forward-looking statements, which speak only as of the date made.

Words such as anticipates, expects, intends, plans, believes, seeks, estimates, may, could, and similar
expressions identify forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q that involve risks and uncertainties include, without limitation:



| |  |  | Managements expectation that gross margin and gross profit may be positively or adversely affected as a result of completed or ongoing requests for proposals;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Managements expectation that as the average wholesale price of pharmaceuticals move up or down, revenue and cost of revenue move correspondingly, leaving
gross profit margins largely unaffected, or that the use of generic drug pricing will improve profit margins;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Managements expectation that tax benefits will be utilized through the reversal of deferred tax liabilities in future periods;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------



| |  |  | Managements expectations and estimates of revenue impact, net income impact and reassessment of goodwill and/or other intangible assets valuation, and cash
flow impact from the loss of the Liberty Mutual Pharmacy Benefit Management contract; and
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Managements expectation that current levels of operation and anticipated growth, cash from operations, together with other available sources of liquidity,
including borrowings available under its senior secured revolving credit facility, will be sufficient to fund its operations, anticipated capital expenditures and required payments on its debt for at least the next 12 months.
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995,
management is identifying important factors that could affect the Companys financial performance and could cause actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in
any current statements. The Companys future results could be adversely affected by a variety of factors, including:



| |  |  | the Companys dependence on sophisticated data processing software and hardware may impact business operations if they fail to operate properly or not as
anticipated;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the Companys net sales and operating results may fluctuate quarterly;
| | - |  | ----------------------------------------------------------------------



| |  |  | operational disruptions due to natural disasters, particularly in regions susceptible to hurricanes;
| | - |  | ----------------------------------------------------------------------------------------------------



| |  |  | the Companys inability to obtain certain medical supplies, services and pharmaceuticals, due to vendor supply disruptions;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------



| |  |  | increasing competitive pricing pressures on its sales to companies who are self-insured for workers compensation insurance and workers compensation
provider groups;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | government legislation or changes in government regulations that reduce workers compensation reimbursement rates that may have an adverse impact on the
Companys revenues in the Pharmaceutical and Medical Products and Services product lines;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



3



---

##### Table of Contents

| |  |  | the Companys dependence on a limited number of large customers;
| | - |  | ----------------------------------------------------------------



| |  |  | the Companys ability to successfully restructure operations to remove operational and other costs associated with revenue declines due to the loss of a large
customer;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the Company may not be able to continue to compete successfully with other medical supply companies and direct manufacturers;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------



| |  |  | continued consolidation within the healthcare industry may lead to increased competition;
| | - |  | -----------------------------------------------------------------------------------------



| |  |  | the expansion of the multi-tiered pricing structure may place the Company at a competitive disadvantage;
| | - |  | --------------------------------------------------------------------------------------------------------



| |  |  | the Companys dependence on the availability of lower cost, multi-tiered pricing of products;
| | - |  | ---------------------------------------------------------------------------------------------



| |  |  | cost of goods sold may increase due to fuel surcharges from third parties;
| | - |  | --------------------------------------------------------------------------



| |  |  | the Companys dependence on its ability to maintain good relations with customers and vendors;
| | - |  | ----------------------------------------------------------------------------------------------



| |  |  | the loss of any significant agreements or the renegotiation of terms and conditions of existing agreements;
| | - |  | -----------------------------------------------------------------------------------------------------------



| |  |  | the Companys ability to hire and retain qualified sales representatives to continue its sales growth;
| | - |  | ------------------------------------------------------------------------------------------------------



| |  |  | the Companys ability to retain the services of senior management;
| | - |  | ------------------------------------------------------------------



| |  |  | the Companys failure to execute its business plan and strategies for growth;
| | - |  | -----------------------------------------------------------------------------



| |  |  | the Companys level of indebtedness, which may limit its ability to obtain financing in the future and may limit flexibility to react to market conditions;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | tax legislative initiatives and potential interest and penalty exposure related to existing and future tax audits;
| | - |  | ------------------------------------------------------------------------------------------------------------------



| |  |  | litigation and liability exposure for existing and potential claims;
| | - |  | --------------------------------------------------------------------



| |  |  | failure to maintain an effective system of internal controls may impact the Companys ability to accurately report its financial results;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------



| |  |  | failure to comply with Federal and state regulations pertaining to physical security, record-keeping, and required reporting related to the purchase, sale, and
distribution of controlled and legend drugs;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | failure to comply with Federal and state regulations pertaining to filing claims for health care reimbursement or changes in the interpretation of those
requirements;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | willful circumvention of Federal and state regulations pertaining to filing claims for health care reimbursement by Company employees;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------



| |  |  | failure in the proper adoption of new accounting pronouncements or Securities and Exchange Commission rules and regulations; and
| | - |  | --------------------------------------------------------------------------------------------------------------------------------



| |  |  | the ongoing costs of complying with the provisions of Section 404 of the Sarbanes-Oxley Act.
| | - |  | --------------------------------------------------------------------------------------------

In addition, all forward-looking statements are qualified by and should be read in conjunction with the risks described or referred to under the heading
Risk Factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2006 filed with the SEC. We undertake no obligation to revise or publicly release the results of any revision to
these forward-looking statements.



4



---

##### Table of Contents

Part IFinancial Information

Item 1Financial Statements

MSCMedical Services Company

Condensed Balance Sheets

(Dollars in thousands)



|                                                                                                                   |  |              |         |                  |   |        
|------------------------------------------------------------------------------------------------------------------ |  | ------------ | ------- | ---------------- | - | -------
|                                                                                                                   |  | June 30,2007 |         | December 31,2006
|                                                                                                                   |  | (Unaudited)  |         |                 
|Assets                                                                                                             |  |              |         |                  |   |        
|Current assets:                                                                                                    |  |              |         |                  |   |        
|Cash                                                                                                               |  | $            | 5,833   |                  | $ | 6,101  
|Accounts receivable, less allowance of $18,476 at June 30, 2007 and $18,795 at December 31, 2006                   |  |              | 62,243  |                  |   | 63,537 
|Inventories                                                                                                        |  |              | 162     |                  |   | 150    
|Other current assets                                                                                               |  |              | 1,822   |                  |   | 1,104  
|Current deferred income taxes                                                                                      |  |              | 7,962   |                  |   | 7,965  
|                                                                                                                   |  |              |         |                  |   |        
|Total current assets                                                                                               |  |              | 78,022  |                  |   | 78,857 
|Property and equipment, net of accumulated depreciation of $6,650 at June 30, 2007 and $5,196 at December 31, 2006 |  |              | 5,864   |                  |   | 5,801  
|Intangible assets:                                                                                                 |  |              |         |                  |   |        
|Goodwill                                                                                                           |  |              | 236,207 |                  |   | 236,207
|Trademarks                                                                                                         |  |              | 24,100  |                  |   | 24,100 
|Customer relationships, net                                                                                        |  |              | 47,775  |                  |   | 50,225 
|Other Intangibles, net                                                                                             |  |              | 38,121  |                  |   | 40,006 
|                                                                                                                   |  |              |         |                  |   |        
|Total intangible assets                                                                                            |  |              | 346,203 |                  |   | 350,538
|Other assets:                                                                                                      |  |              |         |                  |   |        
|Deferred debt issuance costs, net                                                                                  |  |              | 4,391   |                  |   | 4,959  
|Other                                                                                                              |  |              | 1,028   |                  |   | 921    
|                                                                                                                   |  |              |         |                  |   |        
|Total other assets                                                                                                 |  |              | 5,419   |                  |   | 5,880  
|                                                                                                                   |  |              |         |                  |   |        
|Total assets                                                                                                       |  | $            | 435,508 |                  | $ | 441,076
|                                                                                                                   |  |              |         |                  |   |        

See notes to condensed financial statements.



5



---

##### Table of Contents

MSCMedical Services Company

Condensed Balance SheetsContinued

(Dollars in thousands)



|                                                                                          |  |               |         |   |                  |   |         |  
|----------------------------------------------------------------------------------------- |  | ------------- | ------- | - | ---------------- | - | ------- | -
|                                                                                          |  | June 30, 2007 |         |   | December 31,2006 |  
|                                                                                          |  | (Unaudited)   |         |   |                  |  
|Liabilities and stockholders equity                                                      |  |               |         |   |                  |   |         |  
|Current liabilities:                                                                      |  |               |         |   |                  |   |         |  
|Short-term debt                                                                           |  | $             | 20,120  |   |                  | $ | 20,120  |  
|Accounts payable                                                                          |  |               | 9,754   |   |                  |   | 11,874  |  
|Accrued expenses                                                                          |  |               | 34,430  |   |                  |   | 42,369  |  
|Other current liabilities                                                                 |  |               | 102     |   |                  |   | 3,599   |  
|                                                                                          |  |               |         |   |                  |   |         |  
|Total current liabilities                                                                 |  |               | 64,406  |   |                  |   | 77,962  |  
|                                                                                          |  |              
|Non-current liabilities:                                                                  |  |               |         |   |                  |   |         |  
|Long-term debt, less current portion                                                      |  |               | 149,020 |   |                  |   | 148,895 |  
|Deferred income taxes                                                                     |  |               | 28,928  |   |                  |   | 30,544  |  
|                                                                                          |  |               |         |   |                  |   |         |  
|Total non-current liabilities                                                             |  |               | 177,948 |   |                  |   | 179,439 |  
|                                                                                          |  |               |         |   |                  |   |         |  
|Total liabilities                                                                         |  |               | 242,354 |   |                  |   | 257,401 |  
|Stockholders equity:                                                                     |  |               |         |   |                  |   |         |  
|Common stock, $1.00 par value, 1,000 shares authorized, 100 shares issued and outstanding |  |               |        |   |                  |   |        |  
|Additional paid-in capital                                                                |  |               | 215,256 |   |                  |   | 214,643 |  
|Accumulated other comprehensive income                                                    |  |               | 635     |   |                  |   | 561     |  
|Accumulated Deficit                                                                       |  |               | (22,737 | ) |                  |   | (31,529 | )
|                                                                                          |  |               |         |   |                  |   |         |  
|Total stockholders equity                                                                |  |               | 193,154 |   |                  |   | 183,675 |  
|                                                                                          |  |               |         |   |                  |   |         |  
|Total liabilities and stockholders equity                                                |  | $             | 435,508 |   |                  | $ | 441,076 |  
|                                                                                          |  |               |         |   |                  |   |         |  

See notes to condensed financial statements.



6



---

##### Table of Contents

MSCMedical Services Company

Condensed Statements of Operations

For the Three and Six Months Ended June 30, 2007 and 2006

(Unaudited)

(Dollars in thousands)



|                                                           |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|---------------------------------------------------------- |  | --------------------------- | ------- | - | ------------------------- | - | ------ | ---- |  | - | ------- | - |  | - | ------- | -
|                                                           |  | Three Months Ended June 30, |         |   | Six Months Ended June 30, |  
|                                                           |  | 2007                        |         |   | 2006                      |   |        | 2007 |  |   | 2006    |  
|Net Revenue:                                               |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|Pharmaceutical                                             |  | $                           | 44,006  |   |                           | $ | 43,966 |      |  | $ | 89,958  |   |  | $ | 87,209  |  
|Medical Products & Services                                |  |                             | 38,546  |   |                           |   | 40,130 |      |  |   | 77,985  |   |  |   | 76,568  |  
|                                                           |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|Total net revenue                                          |  |                             | 82,552  |   |                           |   | 84,096 |      |  |   | 167,943 |   |  |   | 163,777 |  
|Cost of Revenue (excluding depreciation and amortization): |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|Pharmaceutical                                             |  |                             | 36,081  |   |                           |   | 36,841 |      |  |   | 73,952  |   |  |   | 73,097  |  
|Medical Products & Services                                |  |                             | 29,086  |   |                           |   | 30,112 |      |  |   | 59,366  |   |  |   | 58,167  |  
|                                                           |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|Total cost of revenue                                      |  |                             | 65,167  |   |                           |   | 66,953 |      |  |   | 133,318 |   |  |   | 131,264 |  
|                                                           |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|Gross profit                                               |  |                             | 17,385  |   |                           |   | 17,143 |      |  |   | 34,625  |   |  |   | 32,513  |  
|                                                           |  |                             |         |  
|Operating expenses                                         |  |                             | 11,537  |   |                           |   | 11,230 |      |  |   | 23,347  |   |  |   | 22,595  |  
|Depreciation and amortization                              |  |                             | 2,854   |   |                           |   | 3,004  |      |  |   | 5,785   |   |  |   | 5,894   |  
|                                                           |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|Total expenses                                             |  |                             | 14,391  |   |                           |   | 14,234 |      |  |   | 29,132  |   |  |   | 28,489  |  
|Litigation settlement                                      |  |                             | (12,363 | ) |                           |   |       |      |  |   | (12,363 | ) |  |   |        |  
|                                                           |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|                                                           |  |                             |         |  
|Operating income                                           |  |                             | 15,357  |   |                           |   | 2,909  |      |  |   | 17,856  |   |  |   | 4,024   |  
|Interest expense, net                                      |  |                             | 5,417   |   |                           |   | 5,266  |      |  |   | 10,711  |   |  |   | 10,275  |  
|                                                           |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|Income (loss) before income taxes                          |  |                             | 9,940   |   |                           |   | (2,357 | )    |  |   | 7,145   |   |  |   | (6,251  | )
|Income tax benefit                                         |  |                             | 597     |   |                           |   | 885    |      |  |   | 1,647   |   |  |   | 2,348   |  
|                                                           |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  
|Net income (loss)                                          |  | $                           | 10,537  |   |                           | $ | (1,472 | )    |  | $ | 8,792   |   |  | $ | (3,903  | )
|                                                           |  |                             |         |   |                           |   |        |      |  |   |         |   |  |   |         |  

See notes to condensed financial statements.



7



---

##### Table of Contents

MSCMedical Services Company

Condensed Statements of Cash Flows

For the Six Months Ended June 30, 2007 and 2006

(Unaudited)

(Dollars in thousands)



|                                                                                                   |  |                           |         |   |      |   |         |  
|-------------------------------------------------------------------------------------------------- |  | ------------------------- | ------- | - | ---- | - | ------- | -
|                                                                                                   |  | Six Months Ended June 30, |        
|                                                                                                   |  | 2007                      |         |   | 2006 |  
|Operating activities                                                                               |  |                           |         |   |      |   |         |  
|Net income (loss)                                                                                  |  | $                         | 8,792   |   |      | $ | (3,903  | )
|Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |  |                           |         |   |      |   |         |  
|Depreciation                                                                                       |  |                           | 1,452   |   |      |   | 1,561   |  
|Amortization of intangibles                                                                        |  |                           | 4,333   |   |      |   | 4,333   |  
|Amortization of debt issuance costs and debt discount                                              |  |                           | 693     |   |      |   | 659     |  
|Provision for deferred income taxes                                                                |  |                           | (1,710  | ) |      |   | (1,754  | )
|Provision for bad debts                                                                            |  |                           | 4,197   |   |      |   | 4,089   |  
|Stock-based compensation                                                                           |  |                           | 751     |   |      |   | 704     |  
|Non-cash gain on litigation settlement                                                             |  |                           | (3,366  | ) |      |   |        |  
|Changes in operating assets and liabilities:                                                       |  |                           |         |   |      |   |         |  
|Increase in accounts receivable                                                                    |  |                           | (2,903  | ) |      |   | (8,735  | )
|(Increase) decrease in inventories                                                                 |  |                           | (12     | ) |      |   | 23      |  
|(Increase) decrease in income tax receivable                                                       |  |                           | (96     | ) |      |   | 7,194   |  
|Increase in other current assets                                                                   |  |                           | (622    | ) |      |   | (378    | )
|Increase in other non-current assets                                                               |  |                           |        |   |      |   | (711    | )
|Increase (decrease) in accounts payable & accrued expenses                                         |  |                           | (10,131 | ) |      |   | 3,808   |  
|Increase (decrease) in deferred revenue                                                            |  |                           | (83     | ) |      |   | 113     |  
|Decrease in income taxes payable                                                                   |  |                           | (48     | ) |      |   | (372    | )
|                                                                                                   |  |                           |         |   |      |   |         |  
|Net cash provided by operating activities                                                          |  |                           | 1,247   |   |      |   | 6,631   |  
|                                                                                                   |  |                           |         |   |      |   |         |  
|Investing activities                                                                               |  |                           |         |   |      |   |         |  
|Purchases of property and equipment                                                                |  |                           | (1,515  | ) |      |   | (2,090  | )
|Payment to former owners                                                                           |  |                           |        |   |      |   | (8,803  | )
|                                                                                                   |  |                           |         |   |      |   |         |  
|Net cash used in investing activities                                                              |  |                           | (1,515  | ) |      |   | (10,893 | )
|                                                                                                   |  |                           |         |   |      |   |         |  
|Financing activities                                                                               |  |                           |         |   |      |   |         |  
|Proceeds from short-term debt                                                                      |  |                           |        |   |      |   |        |  
|Proceeds from long-term debt                                                                       |  |                           |        |   |      |   |        |  
|Repayment of short-term debt                                                                       |  |                           |        |   |      |   |        |  
|Repayment of long-term debt                                                                        |  |                           |        |   |      |   |        |  
|                                                                                                   |  |                           |         |   |      |   |         |  
|Net cash provided by financing activities                                                          |  |                           |        |   |      |   |        |  
|                                                                                                   |  |                           |         |   |      |   |         |  
|Net decrease in cash                                                                               |  |                           | (268    | ) |      |   | (4,262  | )
|Cash, beginning of period                                                                          |  |                           | 6,101   |   |      |   | 8,300   |  
|                                                                                                   |  |                           |         |   |      |   |         |  
|Cash, end of period                                                                                |  | $                         | 5,833   |   |      | $ | 4,038   |  
|                                                                                                   |  |                           |         |   |      |   |         |  

See notes to condensed financial statements.



8



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statements

June 30, 2007

(Dollar amounts
in thousands except per share data, unless otherwise stated)

1. Summary of Significant Accounting Policies

Description of Business

MSC-Medical Services Company
(the Company or MSC) is a provider of healthcare products and services for the workers compensation industry in the United States. The Company provides workers compensation payors, such as insurers and third party
administrators, with a quality alternative to the costly and time-consuming process of coordinating the logistics for the delivery of non-acute care needs to their claimants. MSC currently manages relationships with over 7,000 vendors, enabling it
to provide over 20,000 healthcare products and services to workers compensation patients throughout the United States.

Basis of Presentation

The accompanying condensed unaudited interim financial statements have been prepared in accordance with the rules and regulations of the
United States Securities and Exchange Commission (the SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles
(GAAP) have been omitted pursuant to the SEC rules and regulations for interim reporting. The financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of
operations for the periods indicated. All such adjustments are of a normal, recurring nature. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions about future events that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Operating results for the interim
period reported are not necessarily indicative of the results that may be expected for the year ending December 31, 2007.

The
condensed balance sheet at December 31, 2006 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.

For further information, refer to the financial statements and footnotes thereto included in the Companys Annual Report on Form 10-K for the year
ended December 31, 2006 filed with the SEC.

Allowance for Doubtful Accounts

Additions to the allowance for doubtful accounts are made by means of the provision for bad debts which is based upon managements assessment of
historical and expected collections and other collection indicators. The provision for bad debts includes reserves for specific high-collection risk customer accounts and reserves for other customer collection risks. Such reserves and estimation
factors are reviewed and updated periodically as uncollectible accounts are deducted from the allowance, and subsequent recoveries are added.

Included in the allowance for doubtful accounts are provisions for sales allowances totaling $0.8 million at June 30, 2007 and $0.7 million at June 30, 2006.

Bad debt expense for the six months ended June 30, 2007 and 2006 was approximately $4.2 million and $4.1 million, respectively.



9



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)

Impairment of Long-Lived Assets

Goodwill represents
the excess purchase price paid over net assets acquired resulting from the application of the purchase method of accounting. Goodwill is tested annually for impairment.

Under Statement of Financial Accounting Standards (SFAS) No. 142, Goodwill and Other Intangible Assets, goodwill and intangible assets with indefinite lives are no longer amortized but are
reviewed at least annually for impairment. The Company performed its annual impairment review of goodwill and trademarks as of the measurement date, October 31, for fiscal year 2006, which indicated no impairment charge was required.

The Company evaluates its long-lived assets for impairment whenever circumstances indicate that the carrying amount of the asset may not
be recoverable from estimated future cash flows, in accordance with SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. There were no impairment losses recognized in the six months ended June 30, 2007 nor
in the years ended December 31, 2006 and December 31, 2005.

On March 6, 2007, MSC was provided with notice by Liberty
Mutual of their intent to terminate the Liberty Mutual Pharmacy Benefit Management (PBM) Agreement dated as of April 1, 2003 between the Company and Liberty Mutual. The effective date of the termination of the Liberty Mutual PBM
Agreement was June 4, 2007. MSCs contracts with Liberty Mutual for Home Health Services and Durable Medical Equipment are unaffected. Liberty Mutual represented approximately 19% of the Companys total billings for the year ended
December 31, 2006. Gross billings before sales adjustments from the Liberty Mutual PBM Agreement totaled approximately $42.8 million in 2006. Liberty Mutual also represented 13.9%, or $11.4 million of gross accounts receivable at
December 31, 2006 before reduction for allowance for doubtful accounts. In the first quarter of 2007, the Company tested the valuation of goodwill and other intangible assets in accordance with guidance included in SFAS No. 142,
Goodwill and Other Intangible Assets.As a result of this review, the Company concluded that no impairment had occurred as a result of the termination of the Liberty Mutual PBM Agreement.

Recently Issued Accounting Standards

In June 2006,
the Financial Accounting Standards Board (FASB) issued SFAS No. 155 Accounting for Certain Hybrid Financial Instrumentsan amendment of FASB Statements No. 133 and 140, SFAS No. 156 Accounting for Servicing
of Financial Assetsan amendment of FASB Statement No. 140 and FSP FIN 46(R)-6Determining the Variability to be Considered in Applying FASB Interpretation No. 46(R). The Company has completed its evaluation of the
SFAS pronouncements staff position and concluded that they will not impact the Companys financial statements.

In June 2006, the FASB
issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxesan interpretation of FASB Statement No. 109and subsequently, on May 2, 2007, the FASB also issued FASB Staff Position (FSP) No. FIN
48-1Definition ofSettlementin FASB Interpretation No. 48. This Interpretation and FSP provide guidance for recognizing and measuring tax positions taken or expected to be taken in a tax return that directly
or indirectly affect amounts reported in financial statements, as well as provide accounting guidance for the related income tax effects of tax positions that do not meet the recognition threshold specified in this Interpretation. This
Interpretation is effective for fiscal years beginning after December 15, 2006. The provisions of the FSP are effective upon the initial adoption of FIN 48. The Company adopted the provisions of these pronouncements effective January 1,
2007 as discussed in further detail in Note 5 of Notes to Unaudited Condensed Financial Statements in this report.

In September 2006, the
FASB issued SFAS No. 157, Fair Value Measurements.This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value
measurements. This Statement applies under other accounting pronouncements that require or permit fair value measurements, the Board having previously concluded in those accounting pronouncements that fair value is the relevant measurement
attribute. Accordingly, this Statement does not require any new fair value measurements. This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal
years. Earlier application is encouraged,



10



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)

provided that the reporting entity has not yet issued financial statements for that fiscal year, including financial statements for an interim period within that fiscal
year. The Company has not completed its evaluation of the impact of adopting this pronouncement.

In February 2007, the FASB issued
SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities. This pronouncement would permit entities to elect to measure financial instruments and certain other items at fair value at specified election
dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected would be reported in earnings. This statement is effective for fiscal periods beginning after November 15, 2007; early adoption is only
permitted for companies that have also elected to apply the provisions of SFAS No. 157, Fair Value Measurements as discussed above. The Company has not completed its evaluation of the impact of adopting this pronouncement.

2. Stock Based Compensation

Effective
January 1, 2006, the Company adopted SFAS No. 123(R), Share-Based Payment, (SFAS No. 123(R)) applying the modified prospective method. SFAS No. 123(R) requires all equity-based payments to employees, including grants
of employee stock options, to be recognized in the statement of earnings based on the grant date fair value of the award. Under the modified prospective method, the Company is required to record equity-based compensation expense for all awards
granted after the date of adoption and for the unvested portion of previously granted awards outstanding as of the date of adoption. The fair values of stock options granted during 2005 and after the Company adopted SFAS No. 123(R) were
determined using a Black-Scholes valuation model.

In adopting SFAS No. 123(R), the Company did not modify the terms of any previously
granted options.

The fair value of restricted shares is determined by the number of shares granted and the grant date fair value of the
Companys Common Shares. The compensation expense recognized for all equity-based awards is net of estimated forfeitures and is recognized over the awards service period. In accordance with Staff Accounting Bulletin (SAB)
No. 107, the Company classified equity-based compensation within operating expenses to correspond with the same line item as the majority of the cash compensation paid to employees.

The impact of the equity-based compensation is reflected in cash flow from operations on the Condensed Statement of Cash Flows.

Activity relative to the Companys common stock options is as follows:



|                                         |  |                  |   |  |                                          |       |   |                                                     |      |                              |   |      
|---------------------------------------- |  | ---------------- | - |  | ---------------------------------------- | ----- | - | --------------------------------------------------- | ---- | ---------------------------- | - | -----
|                                         |  | Number of Shares |   |  | Weighted Average ExercisePrice Per Share |       |   | Weighted Average Remaining ContractualLife in Years |      | Intrinsic Value ($ in 000s)
|Options outstanding at December 31, 2006 |  | 29,782,003       |   |  | $                                        | 1.34  |   |                                                     | 8.48 |                              | $ | 1,789
|Options grantedtime vesting             |  | 2,438,357        |   |  | $                                        | 1.50  |   |                                                     |      |                              |   |      
|Options grantedperformance vesting      |  | 1,219,179        |   |  | $                                        | 1.50  |   |                                                     |      |                              |   |      
|Options forfeited                        |  | (986,386         | ) |  | $                                        | (1.50 | ) |                                                     |      |                              |   |      
|                                         |  |                  |   |  |                                          |       |   |                                                     |      |                              |   |      
|Options outstanding at March 31, 2007    |  | 32,453,153       |   |  | $                                        | 1.36  |   |                                                     | 8.42 |                              | $ | 1,750
|Options grantedtime vesting             |  |                 |   |  |                                          |      |   |                                                     |      |                              |   |      
|Options grantedperformance vesting      |  |                 |   |  |                                          |      |   |                                                     |      |                              |   |      
|Options forfeited                        |  | (1,081,430       | ) |  | $                                        | (1.50 | ) |                                                     |      |                              |   |      
|                                         |  |                  |   |  |                                          |       |   |                                                     |      |                              |   |      
|Options outstanding at June 30, 2007     |  | 31,371,723       |   |  | $                                        | 1.34  |   |                                                     | 8.43 |                              |   |      
|                                         |  |                  |   |  |                                          |       |   |                                                     |      |                              |   |      
|Exercisable at June 30, 2007             |  | 14,770,752       |   |  | $                                        | 1.16  |   |                                                     | 8.18 |                              | $ | 1,903
|                                         |  |                  |   |  |                                          |       |   |                                                     |      |                              |   |      



11



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)

Two-thirds of options granted vest over a three-year period, with an exercise price ranging from $1.00 to $3.00. The remaining one-third vest only upon
change in control and also have exercise prices ranging from $1.00 to $3.00. Any portion of the stock options not then vested shall immediately vest. The 14.8 million vested shares at June 30, 2007 have exercise prices between $0.29 and
$3.00.

The fair value of options granted during the first quarter of 2007 was approximately $0.2 million and is expected to be expensed
over a period of 36 months. No options were granted during the second quarter of 2007.

The estimated fair value of each option granted
after January 1, 2006 is calculated using the Black-Scholes option pricing model. The assumptions used for calculating fair value of grants issued during the first quarter of 2007 varied in range as follows: expected life of 2.5 to 2.67 years,
risk-free interest rate of 4.5%  4.8%, expected volatility of 20.5%  21.4% and no expected dividend yield.

An estimated
expected life of 3 years before exercise was used for the grants during the six months ended June 30, 2007, based on the typical investment holding period of the shareholder with a controlling interest in MSC. A targeted holding period range of
three to six years is cited in Monitor Clipper Equity Partners II, L.P. Private Placement Memorandumat which time all shares would be expected to be vested and then exercised. Implicit in this assumption is that option-holders would not
likely exercise before a transaction date as they would become the holders of minority interest shares subject to marketability discounts should they wish to sell their shares. The expected change in control will likely provide a liquidity event for
option-holders.

In order to calculate volatility, the Company analyzed the publicly traded stock options of guideline companies with
respect to implied volatility. Implied volatilities were calculated using an average of the 10-day trailing 720-day term to expiration on at the money options as of the valuation date. The Company relied exclusively on the median implied
volatility as a proxy for expected volatility in the Black-Scholes model as the Company believes it provides the best indication of expected volatility over the expected lives of the options.

Activity relative to the Companys restricted stock is as follows



|                                                   |  |                  |   |  |                          |    
|-------------------------------------------------- |  | ---------------- | - |  | ------------------------ | ---
|                                                   |  | Number of Shares |   |  | Fair value at grant date
|Restricted shares outstanding at December 31, 2006 |  | 900,000          |   |  | $                        | .88
|Issued during first quarter                        |  | 550,000          |   |  | $                        | .81
|Shares vested                                      |  | (300,000         | ) |  |                          |    
|                                                   |  |                  |   |  |                          |    
|Restricted shares outstanding at June 30, 2007     |  | 1,150,000        |   |  |                          |    
|                                                   |  |                  |   |  |                          |    

The restricted shares issued prior to 2007 were issued at a purchase price of $0.001 per share
with one-third of the options vesting on February 14 of each of 2007, 2008 and 2009. The restricted shares issued during 2007 were issued at a purchase price of $0.001 per share with one-third of the shares vesting in March of each of 2008,
2009 and 2010.

3. Comprehensive Income

Comprehensive income represents all changes in equity of the enterprise that results from recognized transactions and other economic events during the period. Other comprehensive (loss) income refers to revenues, expenses, gains, and losses
that under GAAP are included in comprehensive income but excluded from net income, such as the unrealized gain or loss on the Companys interest rate swap. The following table details the components of comprehensive income (loss) for the
periods presented.



12



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)



|                                                  |  |                     |        |               |                  |        |               |  |               |       |  |   |        |  
|------------------------------------------------- |  | ------------------- | ------ | ------------- | ---------------- | ------ | ------------- |  | ------------- | ----- |  | - | ------ | -
|                                                  |  | Three Months Ended, |        |               | Six Months Ended |       
|($ in 000s)                                      |  | June 30, 2007       |        | June 30, 2006 |                  |        | June 30, 2007 |  | June 30, 2006 |      
|Net income (loss)                                 |  | $                   | 10,537 |               | $                | (1,472 | )             |  | $             | 8,792 |  | $ | (3,903 | )
|Other comprehensive income:                       |  |                     |        |               |                  |        |               |  |               |       |  |   |        |  
|Unrealized gain on interest rate swap, net of tax |  |                     | 330    |               |                  | 488    |               |  |               | 74    |  |   | 1,213  |  
|                                                  |  |                     |        |               |                  |        |               |  |               |       |  |   |        |  
|Comprehensive income (loss)                       |  | $                   | 10,867 |               | $                | (984   | )             |  | $             | 8,866 |  | $ | (2,690 | )
|                                                  |  |                     |        |               |                  |        |               |  |               |       |  |   |        |  

4. Commitments and Contingencies

In conjunction with the sale of the Company in March 2005, an escrow account was established with Wells Fargo Bank as the escrow agent and $15.0 million
of the purchase price was deposited in the escrow account to be used as security for and to satisfy claims arising out of the transaction. On May 26, 2006, the parent delivered to the stockholder representative for the sellers of
the Company an indemnification claim against the escrow balance. A $12.4 million settlement was reached on May 30, 2007 by and between the Company and the sellers as part of a settlement agreement that included a cash settlement to the Company
paid out from the escrow account of $9 million and forfeiture of $3.4 million of unpaid tax benefits due to the seller. Consistent with applicable accounting standards and SEC guidance, this transaction has been accounted for as an adjustment to
results of operations in the second quarter of 2007.

5. Income Taxes

In June 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxesan interpretation of FASB Statement No. 109 (FIN 48). This Interpretation and
related guidance prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition,
classification, interest and penalties, accounting in interim periods, disclosures, and transitions.

Effective January 1, 2007, the
Company adopted the provisions of FIN 48 and related guidance. As of January 1, 2007, the unrecognized tax benefit amount recorded was $0.2 million of which $0.1 million would affect income tax expense if recognized. There were no significant
changes to this amount during the first six months of 2007.

Our policy is to recognize interest and penalties accrued on any unrecognized
tax benefits as a component of income tax expense. As of the date of adoption and as of June 30, 2007, the Company did not have accrued interest or penalties associated with any unrecognized tax benefits, nor were any interest or penalties
recognized during the first six months of 2007.

Our evaluation was based on the federal and state income tax years we believe remain open
for examination, 2002 through 2006, and 1999 through 2006, respectively. While the Company believes it has an appropriate basis and documentation to support all income tax positions taken on its tax returns, it is reasonably possible that a
reduction in anticipated income tax benefits could result from such examinations.

The Company is presently under audit by federal
authorities for the tax period ended March 31, 2005. The Company believes that its income tax filing positions and deductions will be materially sustained on audit and does not anticipate any adjustments that will result in a material change to
its financial positions. Therefore, no reserves for federal uncertain income tax positions have been recorded pursuant to FIN 48.

Income
tax expense for the three and six month periods ended June 30, 2007 differed from our normal effective tax rate, as the litigation settlement gain recognized during the second quarter of 2007 is non-taxable. Excluding the impact of this
non-taxable gain, the Companys effective tax rate remained consistent with the prior year.



13



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)

6. Subsequent Event

On July 23, 2007, the
Company repaid $3.5 million of borrowings under the revolving credit facility, which reduced the outstanding short-term debt to $16.6 million.



14



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)

7. Guarantor Financial Statements

The Companys
senior secured floating rate notes are guaranteed by the Parent (also referred to as the Guarantor) on a senior secured basis. The notes are the Companys and the Guarantors senior secured obligation and will rank equally in
right of payment with all of the Companys and Guarantors existing and future unsubordinated indebtedness. The notes are effectively junior to the Companys and Guarantors indebtedness under the Companys senior secured
revolving credit facility to the extent of the value of the assets securing such facility. The notes are secured by a second priority lien on substantially all of the Companys and Guarantors existing and future assets, as well as capital
stock. The senior secured revolving credit facility is secured by a first priority lien on all such assets.

The Company has not presented
separate financial statements for the Guarantor because it has deemed that such financial statements would not provide investors with any material additional information. Included in the tables below are the condensed consolidating balance sheet as
of June 30, 2007 and December 31, 2006, the condensed consolidating statement of operations for the three and six months ended June 30, 2007 and 2006, and condensed consolidating statement of cash flows for the six months ended
June 30, 2007 and 2006 of: (a) the Parent (Guarantor), (b) the Company, (c) elimination entries necessary to consolidate the Parent with the Company, and (d) the consolidated company, MCPMSC Acquisition, Inc.

MCPMSC Acquisition, Inc.

Condensed Consolidating Balance Sheets



|                                      |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        
|------------------------------------- |  | ---------------------------------------- | ------- | ---------------------------------------- | - | ------------ |  | - | ------------ | - | -------- | - | ------------ |  | ------------ | ------- |  | ------------ | ------- |  | - | -------- | - |  | - | -------
|                                      |  | June 30, 2007                            |         | December 31, 2006                       
|                                      |  | (Parent)                                 |         | (Subsidiary)                             |   | Eliminations |  |   | Consolidated |   | (Parent) |   | (Subsidiary) |  | Eliminations |         |  | Consolidated
|                                      |  | (Dollars in thousands except share data) |         | (Dollars in thousands except share data)
|Assets                                |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        
|Current assets:                       |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        
|Cash                                  |  | $                                        |        |                                          | $ | 5,833        |  | $ |             |   |          | $ | 5,833        |  | $            |        |  | $            | 6,101   |  | $ |         |   |  | $ | 6,101  
|Accounts receivable, net              |  |                                          |        |                                          |   | 62,243       |  |   |             |   |          |   | 62,243       |  |              |        |  |              | 63,537  |  |   |         |   |  |   | 63,537 
|Inventories                           |  |                                          |        |                                          |   | 162          |  |   |             |   |          |   | 162          |  |              |        |  |              | 150     |  |   |         |   |  |   | 150    
|Other current assets                  |  |                                          |        |                                          |   | 1,822        |  |   |             |   |          |   | 1,822        |  |              |        |  |              | 1,104   |  |   |         |   |  |   | 1,104  
|Deferred income taxes                 |  |                                          |        |                                          |   | 7,962        |  |   |             |   |          |   | 7,962        |  |              |        |  |              | 7,965   |  |   |         |   |  |   | 7,965  
|                                      |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        
|Total current assets                  |  |                                          |        |                                          |   | 78,022       |  |   |             |   |          |   | 78,022       |  |              |        |  |              | 78,857  |  |   |         |   |  |   | 78,857 
|                                      |  |                                          |         |                                          |   |              |  |  
|Property and equipment, net           |  |                                          |        |                                          |   | 5,864        |  |   |             |   |          |   | 5,864        |  |              |        |  |              | 5,801   |  |   |         |   |  |   | 5,801  
|                                      |  |                                          |         |                                          |   |              |  |  
|Intangible assets:                    |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        
|Goodwill                              |  |                                          |        |                                          |   | 236,207      |  |   |             |   |          |   | 236,207      |  |              |        |  |              | 236,207 |  |   |         |   |  |   | 236,207
|Trademarks                            |  |                                          |        |                                          |   | 24,100       |  |   |             |   |          |   | 24,100       |  |              |        |  |              | 24,100  |  |   |         |   |  |   | 24,100 
|Customer relationships, net           |  |                                          |        |                                          |   | 47,775       |  |   |             |   |          |   | 47,775       |  |              |        |  |              | 50,225  |  |   |         |   |  |   | 50,225 
|Other intangibles, net                |  |                                          |        |                                          |   | 38,121       |  |   |             |   |          |   | 38,121       |  |              |        |  |              | 40,006  |  |   |         |   |  |   | 40,006 
|                                      |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        
|Total intangible assets               |  |                                          |        |                                          |   | 346,203      |  |   |             |   |          |   | 346,203      |  |              |        |  |              | 350,538 |  |   |         |   |  |   | 350,538
|                                      |  |                                          |         |                                          |   |              |  |  
|Other assets:                         |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        
|Investment in consolidated subsidiary |  |                                          | 192,516 |                                          |   |             |  |   | (192,516     | ) |          |   |             |  |              | 183,114 |  |              |        |  |   | (183,114 | ) |  |   |       
|Deferred debt issuance costs, net     |  |                                          | 608     |                                          |   | 4,391        |  |   |             |   |          |   | 4,999        |  |              | 658     |  |              | 4,959   |  |   |         |   |  |   | 5,617  
|Deferred income taxes/other           |  |                                          | 3,863   |                                          |   | 1,028        |  |   |             |   |          |   | 4,891        |  |              | 2,855   |  |              | 921     |  |   |         |   |  |   | 3,776  
|                                      |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        
|Total other assets                    |  |                                          | 196,987 |                                          |   | 5,419        |  |   | (192,516     | ) |          |   | 9,890        |  |              | 186,627 |  |              | 5,880   |  |   | (183,114 | ) |  |   | 9,393  
|                                      |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        
|Total assets                          |  | $                                        | 196,987 |                                          | $ | 435,508      |  | $ | (192,516     | ) |          | $ | 439,979      |  | $            | 186,627 |  | $            | 441,076 |  | $ | (183,114 | ) |  | $ | 444,589
|                                      |  |                                          |         |                                          |   |              |  |   |              |   |          |   |              |  |              |         |  |              |         |  |   |          |   |  |   |        



15



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)

Condensed Consolidating Balance Sheetscontinued



|                                                                                                                                               |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  
|---------------------------------------------------------------------------------------------------------------------------------------------- |  | ---------------------------------------- | ------- | - | ---------------------------------------- | - | ------- | ------------ |  | - | ------------ | - |  | -------- | ------- | - | ------------ | - | ------- | ------------ |  | - | ------------ | - |  | - | -------- | - |  | - | ------- | -
|                                                                                                                                               |  | June 30, 2007                            |         |   | December 31, 2006                        |  
|                                                                                                                                               |  | (Parent)                                 |         |   | (Subsidiary)                             |   |         | Eliminations |  |   | Consolidated |   |  | (Parent) |         |   | (Subsidiary) |   |         | Eliminations |  |   | Consolidated |  
|                                                                                                                                               |  | (Dollars in thousands except share data) |         |   | (Dollars in thousands except share data) |  
|Liabilities and stockholders equity                                                                                                           |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  
|Current liabilities:                                                                                                                           |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  
|Short-term debt                                                                                                                                |  | $                                        |        |   |                                          | $ | 20,120  |              |  | $ |             |   |  | $        | 20,120  |   |              | $ |        |              |  | $ | 20,120       |   |  | $ |         |   |  | $ | 20,120  |  
|Accounts payable                                                                                                                               |  |                                          |        |   |                                          |   | 9,754   |              |  |   |             |   |  |          | 9,754   |   |              |   |        |              |  |   | 11,874       |   |  |   |         |   |  |   | 11,874  |  
|Accrued expenses                                                                                                                               |  |                                          | 886     |   |                                          |   | 34,430  |              |  |   |             |   |  |          | 35,316  |   |              |   | 817     |              |  |   | 42,369       |   |  |   |         |   |  |   | 43,186  |  
|Other current liabilities                                                                                                                      |  |                                          |        |   |                                          |   | 102     |              |  |   |             |   |  |          | 102     |   |              |   |        |              |  |   | 3,599        |   |  |   |         |   |  |   | 3,599   |  
|                                                                                                                                               |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  
|Total current liabilities                                                                                                                      |  |                                          | 886     |   |                                          |   | 64,406  |              |  |   |             |   |  |          | 65,292  |   |              |   | 817     |              |  |   | 77,962       |   |  |   |         |   |  |   | 78,779  |  
|                                                                                                                                               |  |                                          |         |   |                                          |   |         |             
|Non-current liabilities:                                                                                                                       |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  
|Long-term debt                                                                                                                                 |  |                                          | 38,733  |   |                                          |   | 149,020 |              |  |   |             |   |  |          | 187,753 |   |              |   | 36,241  |              |  |   | 148,895      |   |  |   |         |   |  |   | 185,136 |  
|Deferred income taxes                                                                                                                          |  |                                          |        |   |                                          |   | 28,928  |              |  |   |             |   |  |          | 28,928  |   |              |   |        |              |  |   | 30,544       |   |  |   |         |   |  |   | 30,544  |  
|                                                                                                                                               |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  
|Total non-current liabilities                                                                                                                  |  |                                          | 38,733  |   |                                          |   | 177,948 |              |  |   |             |   |  |          | 216,681 |   |              |   | 36,241  |              |  |   | 179,439      |   |  |   |         |   |  |   | 215,680 |  
|                                                                                                                                               |  |                                          |         |   |                                          |   |         |             
|Total liabilities                                                                                                                              |  |                                          | 39,619  |   |                                          |   | 242,354 |              |  |   |             |   |  |          | 281,973 |   |              |   | 37,058  |              |  |   | 257,401      |   |  |   |         |   |  |   | 294,459 |  
|Stockholders equity:                                                                                                                          |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  
|                                                                                                                                               |  |                                          |         |   |                                          |   |         |             
|Common stock, $.001 par value, 225,000,000 shares authorized, 181,375,000 shares issued and outstanding at June 30, 2007 and
December 31, 2006 |  |                                          | 181     |   |                                          |   |        |              |  |   |             |   |  |          | 181     |   |              |   | 181     |              |  |   |              |   |  |   |          |   |  |   | 181     |  
|Additional paid-in capital                                                                                                                     |  |                                          | 186,201 |   |                                          |   | 215,256 |              |  |   | (215,256     | ) |  |          | 186,201 |   |              |   | 185,590 |              |  |   | 214,643      |   |  |   | (214,643 | ) |  |   | 185,590 |  
|Accumulated other comprehensive income                                                                                                         |  |                                          |        |   |                                          |   | 635     |              |  |   |             |   |  |          | 635     |   |              |   |         |              |  |   | 561          |   |  |   |          |   |  |   | 561     |  
|Accumulated deficit                                                                                                                            |  |                                          | (29,014 | ) |                                          |   | (22,737 | )            |  |   | 22,737       |   |  |          | (29,014 | ) |              |   | (36,202 | )            |  |   | (31,529      | ) |  |   | 31,529   |   |  |   | (36,202 | )
|                                                                                                                                               |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  
|Total stockholders equity                                                                                                                     |  |                                          | 157,368 |   |                                          |   | 193,154 |              |  |   | (192,516     | ) |  |          | 158,006 |   |              |   | 149,569 |              |  |   | 183,675      |   |  |   | (183,114 | ) |  |   | 150,130 |  
|                                                                                                                                               |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  
|Total liabilities and stockholders equity                                                                                                     |  | $                                        | 196,987 |   |                                          | $ | 435,508 |              |  | $ | (192,516     | ) |  | $        | 439,979 |   |              | $ | 186,627 |              |  | $ | 441,076      |   |  | $ | (183,114 | ) |  | $ | 444,589 |  
|                                                                                                                                               |  |                                          |         |   |                                          |   |         |              |  |   |              |   |  |          |         |   |              |   |         |              |  |   |              |   |  |   |          |   |  |   |         |  



16



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)

MCPMSC Acquisition, Inc.

Condensed Consolidating Statement of Operations

For the three months ended



|                                                 |  |                        |        |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |        |   |  |   |       |  |   |        |  
|------------------------------------------------ |  | ---------------------- | ------ | ------------ | ---------------------- | ------- | ------------ |  | - | ------------ | - |  | -------- | ------- | - | ------------ | - | ------ | ------------ |  | ------------ | ------ | - |  | - | ----- |  | - | ------ | -
|                                                 |  | June 30, 2007          |        |              | June 30, 2006          |        
|                                                 |  | (Parent)               |        | (Subsidiary) |                        |         | Eliminations |  |   | Consolidated |   |  | (Parent) |         |   | (Subsidiary) |   |        | Eliminations |  | Consolidated |       
|                                                 |  | (Dollars in thousands) |        |              | (Dollars in thousands) |        
|Net revenue                                      |  | $                      |       |              | $                      | 82,552  |              |  | $ |             |   |  | $        | 82,552  |   |              | $ |       |              |  | $            | 84,096 |   |  | $ |      |  | $ | 84,096 |  
|Cost of revenue                                  |  |                        |       |              |                        | 65,167  |              |  |   |              |   |  |          | 65,167  |   |              |   |       |              |  |              | 66,953 |   |  |   |      |  |   | 66,953 |  
|Gross profit                                     |  |                        |       |              |                        | 17,385  |              |  |   |             |   |  |          | 17,385  |   |              |   |       |              |  |              | 17,143 |   |  |   |      |  |   | 17,143 |  
|Operating expenses                               |  |                        |       |              |                        | 11,537  |              |  |   |             |   |  |          | 11,537  |   |              |   |       |              |  |              | 11,230 |   |  |   |      |  |   | 11,230 |  
|Depreciation and amortization                    |  |                        |       |              |                        | 2,854   |              |  |   |             |   |  |          | 2,854   |   |              |   |       |              |  |              | 3,004  |   |  |   |      |  |   | 3,004  |  
|                                                 |  |                        |        |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |        |   |  |   |       |  |   |        |  
|Total expenses                                   |  |                        |       |              |                        | 14,391  |              |  |   |             |   |  |          | 14,391  |   |              |   |       |              |  |              | 14,234 |   |  |   |      |  |   | 14,234 |  
|Litigation settlement                            |  |                        |       |              |                        | (12,363 | )            |  |   |             |   |  |          | (12,363 | ) |              |   |       |              |  |              |       |   |  |   |      |  |   |       |  
|                                                 |  |                        |        |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |        |   |  |   |       |  |   |        |  
|Operating income                                 |  |                        |       |              |                        | 15,357  |              |  |   |             |   |  |          | 15,357  |   |              |   |       |              |  |              | 2,909  |   |  |   |      |  |   | 2,909  |  
|Equity in gain (loss) of consolidated subsidiary |  |                        | 10,537 |              |                        |        |              |  |   | (10,537      | ) |  |          |        |   |              |   | (1,472 | )            |  |              |       |   |  |   | 1,472 |  |   |       |  
|Other (expense) income:                          |  |                        |        |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |        |   |  |   |       |  |   |        |  
|Interest expense, net                            |  |                        | 1,324  |              |                        | 5,417   |              |  |   |             |   |  |          | 6,741   |   |              |   | 1,134  |              |  |              | 5,266  |   |  |   |      |  |   | 6,400  |  
|                                                 |  |                        |        |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |        |   |  |   |       |  |   |        |  
|Income (loss) before income taxes                |  |                        | 9,213  |              |                        | 9,940   |              |  |   | (10,537      | ) |  |          | 8,616   |   |              |   | (2,606 | )            |  |              | (2,357 | ) |  |   | 1,472 |  |   | (3,491 | )
|Income tax benefit                               |  |                        | 521    |              |                        | 597     |              |  |   |             |   |  |          | 1,118   |   |              |   | 426    |              |  |              | 885    |   |  |   |      |  |   | 1,311  |  
|                                                 |  |                        |        |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |        |   |  |   |       |  |   |        |  
|Net income (loss)                                |  | $                      | 9,734  |              | $                      | 10,537  |              |  | $ | (10,537      | ) |  | $        | 9,734   |   |              | $ | (2,180 | )            |  | $            | (1,472 | ) |  | $ | 1,472 |  | $ | (2,180 | )
|                                                 |  |                        |        |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |        |   |  |   |       |  |   |        |  



17



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)

MCPMSC Acquisition, Inc.

Condensed Consolidating Statement of Operationscontinued

For the six months ended



|                                                 |  |                        |       |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |         |   |  |   |       |  |   |         |  
|------------------------------------------------ |  | ---------------------- | ----- | ------------ | ---------------------- | ------- | ------------ |  | - | ------------ | - |  | -------- | ------- | - | ------------ | - | ------ | ------------ |  | ------------ | ------- | - |  | - | ----- |  | - | ------- | -
|                                                 |  | June 30, 2007          |       |              | June 30, 2006          |        
|                                                 |  | (Parent)               |       | (Subsidiary) |                        |         | Eliminations |  |   | Consolidated |   |  | (Parent) |         |   | (Subsidiary) |   |        | Eliminations |  | Consolidated |        
|                                                 |  | (Dollars in thousands) |       |              | (Dollars in thousands) |        
|Net revenue                                      |  | $                      |      |              | $                      | 167,943 |              |  | $ |             |   |  | $        | 167,943 |   |              | $ |       |              |  | $            | 163,777 |   |  | $ |      |  | $ | 163,777 |  
|Cost of revenue                                  |  |                        |      |              |                        | 133,318 |              |  |   |              |   |  |          | 133,318 |   |              |   |       |              |  |              | 131,264 |   |  |   |      |  |   | 131,264 |  
|Gross profit                                     |  |                        |      |              |                        | 34,625  |              |  |   |             |   |  |          | 34,625  |   |              |   |       |              |  |              | 32,513  |   |  |   |      |  |   | 32,513  |  
|Operating expenses                               |  |                        |      |              |                        | 23,347  |              |  |   |             |   |  |          | 23,347  |   |              |   |       |              |  |              | 22,595  |   |  |   |      |  |   | 22,595  |  
|Depreciation and amortization                    |  |                        |      |              |                        | 5,785   |              |  |   |             |   |  |          | 5,785   |   |              |   |       |              |  |              | 5,894   |   |  |   |      |  |   | 5,894   |  
|                                                 |  |                        |       |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |         |   |  |   |       |  |   |         |  
|Total expenses                                   |  |                        |      |              |                        | 29,132  |              |  |   |             |   |  |          | 29,132  |   |              |   |       |              |  |              | 28,489  |   |  |   |      |  |   | 28,489  |  
|Litigation settlement                            |  |                        |       |              |                        | (12,363 | )            |  |   |              |   |  |          | (12,363 | ) |              |   |       |              |  |              |        |   |  |   |      |  |   |        |  
|                                                 |  |                        |       |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |         |   |  |   |       |  |   |         |  
|Operating income                                 |  |                        |      |              |                        | 17,856  |              |  |   |             |   |  |          | 17,856  |   |              |   |       |              |  |              | 4,024   |   |  |   |      |  |   | 4,024   |  
|Equity in gain (loss) of consolidated subsidiary |  |                        | 8,792 |              |                        |        |              |  |   | (8,792       | ) |  |          |        |   |              |   | (3,903 | )            |  |              |        |   |  |   | 3,903 |  |   |        |  
|Other (expense) income:                          |  |                        |       |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |         |   |  |   |       |  |   |         |  
|Interest expense, net                            |  |                        | 2,608 |              |                        | 10,711  |              |  |   |             |   |  |          | 13,319  |   |              |   | 2,267  |              |  |              | 10,275  |   |  |   |      |  |   | 12,542  |  
|                                                 |  |                        |       |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |         |   |  |   |       |  |   |         |  
|Income (loss) before income taxes                |  |                        | 6,184 |              |                        | 7,145   |              |  |   | (8,792       | ) |  |          | 4,537   |   |              |   | (6,170 | )            |  |              | (6,251  | ) |  |   | 3,903 |  |   | (8,518  | )
|Income tax benefit                               |  |                        | 1,004 |              |                        | 1,647   |              |  |   |             |   |  |          | 2,651   |   |              |   | 851    |              |  |              | 2,348   |   |  |   |      |  |   | 3,199   |  
|                                                 |  |                        |       |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |         |   |  |   |       |  |   |         |  
|Net income (loss)                                |  | $                      | 7,188 |              | $                      | 8,792   |              |  | $ | (8,792       | ) |  | $        | 7,188   |   |              | $ | (5,319 | )            |  | $            | (3,903  | ) |  | $ | 3,903 |  | $ | (5,319  | )
|                                                 |  |                        |       |              |                        |         |              |  |   |              |   |  |          |         |   |              |   |        |              |  |              |         |   |  |   |       |  |   |         |  



18



---

##### Table of Contents

MSCMedical Services Company

Notes to Unaudited Condensed Financial Statementscontinued

June 30, 2007

(Dollar amounts in thousands except per share data, unless otherwise stated)

MCPMSC Acquisition, Inc.

Condensed Consolidating Statement of Cash Flows

For the six months ended



|                                                                                                   |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|-------------------------------------------------------------------------------------------------- |  | ---------------------- | ------ | - | ---------------------- | - | ------- | ------------ |  | - | ------------ | - |  | -------- | ------ | - | ------------ | - | ------ | ------------ |  | - | ------------ | - |  | - | ------ | - |  | - | ------- | -
|                                                                                                   |  | June 30, 2007          |        |   | June 30, 2006          |  
|                                                                                                   |  | (Parent)               |        |   | (Subsidiary)           |   |         | Eliminations |  |   | Consolidated |   |  | (Parent) |        |   | (Subsidiary) |   |        | Eliminations |  |   | Consolidated |  
|                                                                                                   |  | (Dollars in thousands) |        |   | (Dollars in thousands) |  
|Operating activities                                                                               |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Net income (loss)                                                                                  |  | $                      | 7,188  |   |                        | $ | 8,792   |              |  | $ | (8,792       | ) |  | $        | 7,188  |   |              | $ | (5,319 | )            |  | $ | (3,903       | ) |  | $ | 3,903  |   |  | $ | (5,319  | )
|Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Equity in (gain) loss of consolidated subsidiary                                                   |  |                        | (8,792 | ) |                        |   |        |              |  |   | 8,792        |   |  |          |       |   |              |   | 3,903  |              |  |   |             |   |  |   | (3,903 | ) |  |   |        |  
|Depreciation                                                                                       |  |                        |       |   |                        |   | 1,452   |              |  |   |             |   |  |          | 1,452  |   |              |   |       |              |  |   | 1,561        |   |  |   |       |   |  |   | 1,561   |  
|Amortization of intangibles                                                                        |  |                        |       |   |                        |   | 4,333   |              |  |   |             |   |  |          | 4,333  |   |              |   |       |              |  |   | 4,333        |   |  |   |       |   |  |   | 4,333   |  
|Amortization of debt issuance costs and debt discount                                              |  |                        | 95     |   |                        |   | 693     |              |  |   |             |   |  |          | 788    |   |              |   | 129    |              |  |   | 659          |   |  |   |       |   |  |   | 788     |  
|Provision for deferred income taxes                                                                |  |                        | (1,004 | ) |                        |   | (1,710  | )            |  |   |             |   |  |          | (2,714 | ) |              |   | (852   | )            |  |   | (1,754       | ) |  |   |       |   |  |   | (2,606  | )
|Provision for bad debts                                                                            |  |                        |       |   |                        |   | 4,197   |              |  |   |             |   |  |          | 4,197  |   |              |   |       |              |  |   | 4,089        |   |  |   |       |   |  |   | 4,089   |  
|Stock-based compensation                                                                           |  |                        |       |   |                        |   | 751     |              |  |   |             |   |  |          | 751    |   |              |   |       |              |  |   | 704          |   |  |   |       |   |  |   | 704     |  
|Non-cash gain on litigation settlement                                                             |  |                        |        |   |                        |   | (3,366  | )            |  |   |             |   |  |          | (3,366 | ) |              |   |       |              |  |   |             |   |  |   |       |   |  |   |        |  
|Changes in operating assets and liabilities:                                                       |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Increase in accounts receivable                                                                    |  |                        |       |   |                        |   | (2,903  | )            |  |   |             |   |  |          | (2,903 | ) |              |   |       |              |  |   | (8,735       | ) |  |   |       |   |  |   | (8,735  | )
|(Increase) decrease in inventories                                                                 |  |                        |       |   |                        |   | (12     | )            |  |   |             |   |  |          | (12    | ) |              |   |       |              |  |   | 23           |   |  |   |       |   |  |   | 23      |  
|(Increase) decrease in income tax receivable                                                       |  |                        |       |   |                        |   | (96     | )            |  |   |             |   |  |          | (96    | ) |              |   |       |              |  |   | 7,194        |   |  |   |       |   |  |   | 7,194   |  
|Increase in other current assets                                                                   |  |                        |       |   |                        |   | (622    | )            |  |   |             |   |  |          | (622   | ) |              |   |       |              |  |   | (378         | ) |  |   |       |   |  |   | (378    | )
|Increase in other non-current assets                                                               |  |                        |       |   |                        |   |        |              |  |   |             |   |  |          |       |   |              |   |       |              |  |   | (711         | ) |  |   |       |   |  |   | (711    | )
|Increase (decrease) in accounts payable & accrued expenses                                         |  |                        | 2,513  |   |                        |   | (10,131 | )            |  |   |             |   |  |          | (7,618 | ) |              |   | 2,139  |              |  |   | 3,808        |   |  |   |       |   |  |   | 5,947   |  
|Increase (decrease) in deferred revenue                                                            |  |                        |       |   |                        |   | (83     | )            |  |   |             |   |  |          | (83    | ) |              |   |       |              |  |   | 113          |   |  |   |       |   |  |   | 113     |  
|Decrease in income taxes payable                                                                   |  |                        |       |   |                        |   | (48     | )            |  |   |             |   |  |          | (48    | ) |              |   |       |              |  |   | (372         | ) |  |   |       |   |  |   | (372    | )
|                                                                                                   |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Net cash provided by operating activities                                                          |  |                        |       |   |                        |   | 1,247   |              |  |   |             |   |  |          | 1,247  |   |              |   |       |              |  |   | 6,631        |   |  |   |       |   |  |   | 6,631   |  
|                                                                                                   |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Investing activities                                                                               |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Purchases of property and equipment                                                                |  |                        |       |   |                        |   | (1,515  | )            |  |   |             |   |  |          | (1,515 | ) |              |   |       |              |  |   | (2,090       | ) |  |   |       |   |  |   | (2,090  | )
|Payment to former owners                                                                           |  |                        |       |   |                        |   |        |              |  |   |             |   |  |          |       |   |              |   |       |              |  |   | (8,803       | ) |  |   |       |   |  |   | (8,803  | )
|                                                                                                   |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Net cash used in investing activities                                                              |  |                        |       |   |                        |   | (1,515  | )            |  |   |             |   |  |          | (1,515 | ) |              |   |       |              |  |   | (10,893      | ) |  |   |       |   |  |   | (10,893 | )
|                                                                                                   |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Financing activities                                                                               |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Proceeds from (repayments of) short-term debt                                                      |  |                        |       |   |                        |   |        |              |  |   |             |   |  |          |       |   |              |   |       |              |  |   |             |   |  |   |       |   |  |   |        |  
|Proceeds from (repayments of) long-term debt                                                       |  |                        |       |   |                        |   |        |              |  |   |             |   |  |          |       |   |              |   |       |              |  |   |             |   |  |   |       |   |  |   |        |  
|Debt issuance cost                                                                                 |  |                        |       |   |                        |   |        |              |  |   |             |   |  |          |       |   |              |   |       |              |  |   |             |   |  |   |       |   |  |   |        |  
|Capital contribution from Parent company                                                           |  |                        |       |   |                        |   |        |              |  |   |             |   |  |          |       |   |              |   |       |              |  |   |             |   |  |   |       |   |  |   |        |  
|                                                                                                   |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Net cash provided by financing activities                                                          |  |                        |       |   |                        |   |        |              |  |   |             |   |  |          |       |   |              |   |       |              |  |   |             |   |  |   |       |   |  |   |        |  
|                                                                                                   |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Net decrease in cash                                                                               |  |                        |       |   |                        |   | (268    | )            |  |   |             |   |  |          | (268   | ) |              |   |       |              |  |   | (4,262       | ) |  |   |       |   |  |   | (4,262  | )
|Cash, beginning of period                                                                          |  |                        |       |   |                        |   | 6,101   |              |  |   |             |   |  |          | 6,101  |   |              |   |       |              |  |   | 8,300        |   |  |   |       |   |  |   | 8,300   |  
|                                                                                                   |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  
|Cash, end of period                                                                                |  | $                      |       |   |                        | $ | 5,833   |              |  | $ |             |   |  | $        | 5,833  |   |              | $ |       |              |  | $ | 4,038        |   |  | $ |       |   |  | $ | 4,038   |  
|                                                                                                   |  |                        |        |   |                        |   |         |              |  |   |              |   |  |          |        |   |              |   |        |              |  |   |              |   |  |   |        |   |  |   |         |  



19



---

##### Table of Contents

Item 2Managements Discussion and Analysis of Financial Condition and Results of Operations

The following should be read in conjunction with the financial statements and related notes included elsewhere in this report, as well as the financial statements and related notes included in the Companys Annual Report on Form
10-K for the year ended December 31, 2006 as filed with the SEC. In addition, all forward-looking statements are qualified by and should be read in conjunction with the risks described under the heading Forward-Looking Statements of
this Form 10-Q and under the heading Risk Factors included in Part I, Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2006.

Overview

MSCMedical Services Company (We, Us or Our) is
the second largest procurement provider, based on its knowledge of the industry, of health care products and services to workers compensation payors in the United States. We coordinate the delivery of these products and services from our
vendor network to workers compensation patients on behalf of our customers, which include payors such as insurers and third party administrators.

Workers compensation state legislation in the United States generally requires employers to fund the total cost of an employees medical treatment, lost wages and other costs associated with a work-related
injury or illness. Employers are generally required to provide coverage of costs with no co-payment or deductible from the ill or injured employee, and there is typically no lifetime limit on medical expenses. Workers compensation programs
vary across jurisdictions; each state separately determines the level of wage replacement that must be paid and the level of medical care to be provided.

Factors affecting our financial results

Revenue. Revenue consists of amounts charged to customers for the products
and services we provide. Overall, revenue is affected by the size of the workers compensation market for pharmaceutical and medical products and services, federal and state fee schedules mandating maximum billable amounts, the extent of
outsourcing in the industry and any market share changes resulting from shifts with existing customers and new customer wins as well as average wholesale price (AWP) changes for pharmaceuticals. These factors combine to affect the number
of patients served and revenue per patient.

We have identified two distinct product lines consisting of Pharmaceutical products, comprised
primarily of prescription medication, and Medical Products and Services, which describes all other components of revenue. In our Pharmaceuticals product line, revenue per patient reflects costs of new and existing medications, drug prescribing
patterns, drug utilization controls, for example, generic substitution and mix of retail versus mail order fulfillment. In our Medical Products and Services product line, revenue per patient is driven by the nature and quantity of products and
services used by patients, prices we are able to charge our customers for the provision of such products and services as well as federal and state fee schedules mandating maximum billable amounts.

We operate in a competitive market place where revenue may be affected by the competitive bidding process among other service providers. In addition, our
customers may also periodically engage in formal requests for proposals (RFP) on non-contracted, as well as contracted business. We may decide to offer reduced pricing in certain situations given the overall economics of the proposed
business identified in the RFP and the competitive environment. Additionally, there is continuing consolidation within the healthcare industry leading to increased competition. In this regard, one of our non-contracted Ancillary business customers
has recently taken action to consolidate its vendor relationships, thereby reducing the number of vendors they utilize. While this action may have an adverse short-term impact on our Ancillary revenue growth, we continue to believe our competitive
product offering and value proposition affords us opportunities for revenue growth from this industry-wide consolidation in the future.

Cost of Revenue. Cost of revenue consists of payments to vendors for delivery of products and services, customer service representative costs, inventory carrying costs and shipping costs. In our Pharmaceuticals product line, cost of



20



---

##### Table of Contents

revenue also includes credits for vendor rebates, as well as costs related to other service providers (e.g. retail card
distributor). We negotiate prices for the provision of services and products with vendors in our network. In many cases, prices are pre-negotiated under a contract or pre-agreed price list with vendors. Prior to procuring products or services, we
typically obtain written or verbal authorization and pricing approval from customers to minimize reimbursement risk. We also typically finalize the cost of products and services with our vendors before delivery.

Gross Profit. Gross profit reflects the differential between the price at which we sell our products and services and the cost of revenue. Margins
are positively affected when we negotiate lower costs from our vendors without a change in pricing to our customers. Conversely, margins are negatively affected when we lower prices charged to customers without receiving a reduction in costs from
vendors. Examples of this include customer negotiations where we agree to lower prices (for example, volume purchases or length of contracts) as well as certain legislative changes which result in a decrease in pharmaceutical prices that can be
charged. The growth in revenue from the Pharmaceuticals product line (which has lower margins) relative to Medical Products and Services product line revenues has historically lowered our overall margins; however, this impact on margins has been
partially offset by the negotiation of discounts with vendors. Fluctuations in revenue or the cost of revenue do not necessarily result in corresponding changes in gross profit margins. For example, in the Pharmaceuticals product line, the price at
which we are able to procure pharmaceuticals and the prices we charge customers are frequently tied to a common measurement, such as AWP. As the benchmark moves up or down, revenue and cost of revenue move correspondingly, leaving gross profit
margins largely unaffected. Recently, the proportion of generic drugs dispensed has increased. This has generally reduced revenue while improving overall gross margins.

Significant customers.For the six months ended June 30, 2007, our largest customer, Liberty Mutual, accounted for approximately 17% of our billings for the period versus 19% for the six months ended
June 30, 2006. Billings to our top ten customers for the six months ended June 30, 2007 represented 46% of total billings for this period and 48% for the six months ended June 30, 2006.

On March 6, 2007, MSC was provided with notice by Liberty Mutual of their intent to terminate the Liberty Mutual Pharmacy Benefit Management
(PBM) Agreement dated as of April 1, 2003 between the Company and Liberty Mutual. The effective date of the termination of the Liberty Mutual PBM Agreement was June 4, 2007. MSCs contracts with Liberty Mutual for Home
Health Services and Durable Medical Equipment are unaffected. Liberty Mutual represented approximately 19% of the Companys total billings for the year ended December 31, 2006. Gross billings before sales adjustments from the Liberty
Mutual PBM Agreement totaled approximately $42.8 million in the year ended 2006. Gross billings before sales adjustments from the Liberty Mutual PBM Agreement totaled approximately $8.2 million and $17.7 million, respectively, in the three and six
months ended June 30, 2007 as compared to approximately $11.2 million and $22.2 million in the same periods in the prior year.

Operating Expenses. Operating expenses include cash compensation, as well as non-cash compensation associated with stock based compensation, other costs associated with our sales force and general and administrative expenses,
including expenses related to information technology, accounting, human resources, travel, professional fees, corporate overhead and bad debt expenses.



21



---

##### Table of Contents

Results of Operations

Three and Six Months Ended June 30, 2007 compared to June 30, 2006.

Total Revenue



|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   
|----------------------------- |  | ----------------------------------- | ------- | ---- | - | ------------------- |  | - | -------------- | - |  | ---- | --
|                              |  | For the Three Months Ended June 30, |        
|                              |  | 2007                                |         | 2006 |   | Increase (Decrease) |  |   | Percent Change |  
|                              |  | (dollars in thousands)              |         |      |   |                     |  |  
|Pharmaceutical                |  | $                                   | 44,006  |      | $ | 43,966              |  | $ | 40             |   |  | 0.0  | % 
|Medical Products and Services |  |                                     | 38,546  |      |   | 40,130              |  |   | (1,584         | ) |  | (3.9 | )%
|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   
|Total Net Revenue             |  | $                                   | 82,552  |      | $ | 84,096              |  | $ | (1,544         | ) |  | (1.8 | )%
|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   
|                              | 
|                              |  | For the Six Months Ended June 30,   |        
|                              |  | 2007                                |         | 2006 |   | Increase (Decrease) |  |   | Percent Change |  
|                              |  | (dollars in thousands)              |         |      |   |                     |  |  
|Pharmaceutical                |  | $                                   | 89,958  |      | $ | 87,209              |  | $ | 2,749          |   |  | 3.2  | % 
|Medical Products and Services |  |                                     | 77,985  |      |   | 76,568              |  |   | 1,417          |   |  | 1.9  | % 
|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   
|Total Net Revenue             |  | $                                   | 167,943 |      | $ | 163,777             |  | $ | 4,166          |   |  | 2.5  | % 
|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   

Factors contributing to the 1.8% decrease and 2.5% increase, respectively, in revenue during the
three and six month periods ended June 30, 2007, as compared to the prior year, reflect the impact of the continuing implementation of Pharmaceutical services to new customers, offset by the loss of the Liberty Mutual PBM agreement in early
June 2007, combined with favorable pricing adjustments, AWP price increases and product mix shift to higher margin products in our Medical Products and Services product lines, offset by lower order volume in selected product categories and loss of a
non-contracted Ancillary customer.

During the three and six months ended June 30, 2007, we served 2.6% and 1% fewer individual
patients as compared to the same periods in 2006. However, total revenue per patient increased 0.8% and 3.6%, respectively, for the three and six months ended June 30, 2007 as compared to the same periods in 2006. This increase is a result of
several factors including a shift in product mix within the Medical Products and Services lines as described below, as well as pricing adjustments in certain of our product lines, primarily Pharmaceutical products and Medical Products.



22



---

##### Table of Contents

Pharmaceutical Revenue



|                                     |  |                                     |        |      |   |                     |  |   |                |   |  |       |   
|------------------------------------ |  | ----------------------------------- | ------ | ---- | - | ------------------- |  | - | -------------- | - |  | ----- | --
|                                     |  | For the Three Months Ended June 30, |       
|                                     |  | 2007                                |        | 2006 |   | Increase (Decrease) |  |   | Percent Change |  
|                                     |  | (dollars in thousands)              |        |      |   |                     |  |  
|Pharmacy Benefit Management Services |  | $                                   | 41,674 |      | $ | 41,072              |  | $ | 602            |   |  | 1.5   | % 
|Mail Order Services                  |  |                                     | 2,332  |      |   | 2,894               |  |   | (562           | ) |  | (19.4 | )%
|                                     |  |                                     |        |      |   |                     |  |   |                |   |  |       |   
|Total Net Revenue                    |  | $                                   | 44,006 |      | $ | 43,966              |  | $ | 40             |   |  | 0.0   | % 
|                                     |  |                                     |        |      |   |                     |  |   |                |   |  |       |   
|                                     | 
|                                     |  | For the Six Months Ended June 30,   |       
|                                     |  | 2007                                |        | 2006 |   | Increase (Decrease) |  |   | Percent Change |  
|                                     |  | (dollars in thousands)              |        |      |   |                     |  |  
|Pharmacy Benefit Management Services |  | $                                   | 85,067 |      | $ | 81,436              |  | $ | 3,631          |   |  | 4.5   | % 
|Mail Order Services                  |  |                                     | 4,891  |      |   | 5,773               |  |   | (882           | ) |  | (15.3 | )%
|                                     |  |                                     |        |      |   |                     |  |   |                |   |  |       |   
|Total Net Revenue                    |  | $                                   | 89,958 |      | $ | 87,209              |  | $ | 2,749          |   |  | 3.2   | % 
|                                     |  |                                     |        |      |   |                     |  |   |                |   |  |       |   

The increase in Pharmacy Benefit Management Services revenue for the three and six month periods
ended June 30, 2007, as compared to the same periods in 2006, is due primarily to new customer wins and the impact of AWP net price increases, partially offset by the loss of the Liberty Mutual PBM contract in early June of 2007. Excluding
Liberty Mutual, billings for the three and six months ended June 30, 2007 increased by 7.3% and 9.7%, respectively, as compared to the same periods in 2006. The decline in Mail Order Services revenue period over period was due primarily to
(a) attrition of long-term mail order patients who have been in the mail order program since the inception of our retail pharmaceutical services program, (b) improved screening practices designed to identify mail order candidates versus
the historic method of using mail order as the default when adding new patients, (c) implementation of our retail pharmacy card program, and (d) customers unwillingness to aggressively pursue a mail order conversion strategy. All of these
factors combined have resulted in less mail order conversion opportunities despite the economic benefit to the customer.

Total
prescription fills decreased by 5.2% and 2.0%, respectively, for the three and six months ended June 30, 2007 as compared to the same periods in 2006 due to loss of the Liberty Mutual PBM contract in early June, partially offset by prescription
fill increases for other customers. Excluding Liberty Mutual, prescription fills for the three and six months ended June 30, 2007 increased by 2.9% and 3.9%, respectively, as compared to the same periods in 2006. Second quarter revenue was
essentially unchanged compared to the same period in 2006 reflecting a decline related to prescription fills of $2.3 million, shift in mix from brand to generic of $1 million, offset by the impact of favorable pricing of $3.3 million. For the six
months ended June 30 as compared to the prior year, revenue increased by $2.7 million, reflecting a decline related to prescription fills of $1.8 million, shift in mix from brand to generic of $2.0 million, offset by the impact of favorable
pricing of $6.5 million.



23



---

##### Table of Contents

The shift to generic fills is due primarily to industry-wide carrier initiatives that specify a generic
fill if available. Generic prescription fills as a percent of total fills was 67.6% and 67.4%, respectively, for the three and six months ended June 30, 2007 versus 65.9% and 65.8% during the same periods in 2006.

For the three and six months ended June 30, 2007, average AWP per fill increased 6.7% and 7.5%, respectively, while our price as a percent of AWP
decreased 2.2% and 2.9%, respectively, as compared to the same periods in 2006. The decrease in our prices as a percent of AWP resulted from pricing adjustments given to selected customers in fiscal 2006. In March 2007, the Company increased its
prices to its largest customer as a result of its contract termination notice received March 6, 2007.

Medical Products and Services Revenue



|                  |  |                                     |        |      |   |                     |  |   |                |   |  |      |   
|----------------- |  | ----------------------------------- | ------ | ---- | - | ------------------- |  | - | -------------- | - |  | ---- | --
|                  |  | For the Three Months Ended June 30, |       
|                  |  | 2007                                |        | 2006 |   | Increase (Decrease) |  |   | Percent Change |  
|                  |  | (dollars in thousands)              |        |      |   |                     |  |  
|Medical Products  |  | $                                   | 22,749 |      | $ | 24,762              |  | $ | (2,013         | ) |  | (8.1 | )%
|Medical Services  |  |                                     | 15,797 |      |   | 15,368              |  |   | 429            |   |  | 2.8  | % 
|                  |  |                                     |        |      |   |                     |  |   |                |   |  |      |   
|Total Net Revenue |  | $                                   | 38,546 |      | $ | 40,130              |  | $ | (1,584         | ) |  | (4.0 | )%
|                  |  |                                     |        |      |   |                     |  |   |                |   |  |      |   



|                  |  |                                   |        |      |   |                     |  |   |                |   |  |      |   
|----------------- |  | --------------------------------- | ------ | ---- | - | ------------------- |  | - | -------------- | - |  | ---- | --
|                  |  | For the Six Months Ended June 30, |       
|                  |  | 2007                              |        | 2006 |   | Increase (Decrease) |  |   | Percent Change |  
|                  |  | (dollars in thousands)            |        |      |   |                     |  |  
|Medical Products  |  | $                                 | 46,465 |      | $ | 47,263              |  | $ | (798           | ) |  | (1.7 | )%
|Medical Services  |  |                                   | 31,520 |      |   | 29,305              |  |   | 2,215          |   |  | 7.6  | % 
|                  |  |                                   |        |      |   |                     |  |   |                |   |  |      |   
|Total Net Revenue |  | $                                 | 77,985 |      | $ | 76,568              |  | $ | 1,417          |   |  | 1.9  | % 
|                  |  |                                   |        |      |   |                     |  |   |                |   |  |      |   

During the three and six months ended June 30, 2007, total revenue for Medical Products and
Services decreased by 4% and increased by 1.9%, respectively, compared to the same periods in 2006. In the first half of 2007, there has been a shift in products / services mix from Medical Devices and Home Health to other Medical Products and
Services product categories. Revenue for the three and six months ended June 30 reflects the impact of lower product orders, decline in revenue from a non-contracted customer due to its vendor consolidation initiative, offset by an increase in
average billing per order achieved as a result of business process improvement for our more service intensive, higher billing value product lines. Overall orders decreased by 10% in the second quarter and six months ended June 30, as compared
to the prior year. Total average billings per order for all Medical Products and Services increased by 13% for the six months ended June 30, 2007 as compared to the same period in 2006.

For the three and six months ended June 30, Medical Products orders declined by 13.5% and 13.9%, respectively while billings per order increased by
10.6% and 6.3%, respectively. A decline in Medical Device orders of 22% and 18.4%, respectively, in the three and six months ended June 30, as compared to the same periods in the prior year was the result of (a) stricter credit policies,
which were in effect for the first six months of 2007, with several customers, and (b) the action taken by one of our non-contracted Ancillary customers to consolidate their vendor relationships. There was a shift in product mix from Medical
Devices to the Medical Supplies and other product lines, most of which experienced increased billings per order in the three and six month periods ended June 30, 2007 as compared to the same periods in 2006.

Medical Services revenue increased in the three and six month periods ended June 30, 2007 as compared to the same



24



---

##### Table of Contents

periods in 2006, due principally to order volume and price increases in the Transportation product line. Transportation
revenues increased 24.1% and 28.8%, respectively, for the three and six months ended June 30, as compared to the same periods in 2006. A decrease in Home Health orders was offset by a mix shift to higher value services resulting in a net
increase in billings per order for the three and six month periods ended June 30, 2007 as compared to the same periods in 2006.

Cost of Revenue



|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   
|----------------------------- |  | ----------------------------------- | ------- | ---- | - | ------------------- |  | - | -------------- | - |  | ---- | --
|                              |  | For the Three Months Ended June 30, |        
|                              |  | 2007                                |         | 2006 |   | Increase (Decrease) |  |   | Percent Change |  
|                              |  | (dollars in thousands)              |         |      |   |                     |  |  
|Pharmaceutical                |  | $                                   | 36,081  |      | $ | 36,841              |  | $ | (760           | ) |  | (2.1 | )%
|Medical Products and Services |  |                                     | 29,086  |      |   | 30,112              |  | $ | (1,026         | ) |  | (3.4 | )%
|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   
|Total Cost of Revenue         |  | $                                   | 65,167  |      | $ | 66,953              |  | $ | (1,786         | ) |  | (2.7 | )%
|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   
|                              | 
|                              |  | For the Six Months Ended June 30,   |        
|                              |  | 2007                                |         | 2006 |   | Increase (Decrease) |  |   | Percent Change |  
|                              |  | (dollars in thousands)              |         |      |   |                     |  |  
|Pharmaceutical                |  | $                                   | 73,952  |      | $ | 73,097              |  | $ | 855            |   |  | 1.2  | % 
|Medical Products and Services |  | $                                   | 59,366  |      | $ | 58,167              |  | $ | 1,199          |   |  | 2.1  | % 
|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   
|Total Cost of Revenue         |  | $                                   | 133,318 |      | $ | 131,264             |  | $ | 2,054          |   |  | 1.6  | % 
|                              |  |                                     |         |      |   |                     |  |   |                |   |  |      |   

Cost of revenue, as a percentage of revenue, was 78.9% and 79.4%, respectively, for the three and
six month periods ended June 30, 2007, a decrease of 0.7% as compared to the same periods in 2006. This decrease as a percentage of revenue is due to: (a) favorable vendor pricing actions, (b) a more favorable product mix towards
higher margin products and services, and (c) savings achieved from productivity gains of internal operating costs.

The decrease in
Pharmaceutical cost of revenue during the second quarter of 2007 as compared to same period in the prior year is a result of a decrease in the total number of prescription fills primarily attributable to the loss of the Liberty Mutual PBM contract
in early June. This is offset by an increase in the average cost per fill for branded drugs which increased approximately 11% per fill, for the three and six months ended June 30, 2007 as compared to the same periods in 2006. Generic cost
per fill, however, decreased 5.1% and 7.9%, respectively, for the three and six months ended June 30, 2007 as compared to the same periods in 2006. Pricing concessions from selected vendors mitigated the full effect of the net increased price
per fill. Although there was a 1.2% increase in Pharmaceutical cost of revenue for the six months ended June 30 as compared to the prior year, the same cost dynamics are applicable to this period as explained above for the quarter.

Medical Products and Services cost of revenue changes are primarily a result of product mix shifts, as discussed in Medical Products and Services
Revenueabove. Medical Products and Services gross margin for the three and six months ended June 30, 2007 was 24.5% and 23.9%, respectively, as compared to 25.0% and 24.0% during the same periods in 2006. The impacts of favorable vendor
pricing actions during the first six months were offset by lower order volume and higher service costs.



25



---

##### Table of Contents

Operating Expenses

Operating expenses were $11.5 million and $23.3 million for the three and six months ended June 30, 2007 as compared to $11.2 million and $22.6 million in the same periods in 2006. For both years, in the three
and six months ended June 30, non-cash stock compensation expense of $0.4 million and $0.7 million, respectively, was incurred. Expenses increased by $0.2 million and $0.3 million, respectively, for the three and six months ended June 30,
2007, as compared to the same periods in 2006 related to salaries and benefits costs as a result of increased incentive programs combined with an increase in the number of employees, including temporary workers. In addition, for the quarter and six
months, we incurred $0.2 and $0.5 million, respectively, of increased professional fees as consultants were hired to assist in various projects, e.g. efforts to comply with the internal control requirements outlined in the Sarbanes-Oxley Act of
2002, HIPPA compliance program as well as other operational consulting projects. These increases were partially offset by a decrease in certain expenses incurred in the first quarter of 2006 associated with the filing of a registration statement and
severance costs. Second quarter of 2007 results reflect the impact of a lower sales tax accrual as well as a lower incentive compensation accrual based on year-to-date financial performance.

Bad debt expense, which is included as a component of operating expense, was $2.1 million and $4.2 million in the three and six months ended
June 30, 2007 as compared to $2.0 million and $4.1 million in the same periods in 2006. Actual bad debt expense experience for the quarter and the first six months continues to perform favorably to our current provisioning rate of 2.5%. This is
a continuation of a trend noted since the first quarter of 2006 and is reflective of ongoing process improvement initiatives. We continue to evaluate our requirements for specific reserves on a quarterly basis as part of the overall bad debt reserve
analysis.

Depreciation and Amortization expense for the three and six month periods ended June 30, 2007 amounted to $2.9
million and $5.8 million as compared to $3.0 million and $5.9 million in the same periods in 2006. The decrease is attributed to lower capital expenditures during the first six months of 2007.

Litigation Settlement.In conjunction with the sale of the Company in March 2005, an escrow account was established with Wells Fargo Bank as the
escrow agent and $15.0 million of the purchase price was deposited in the escrow account to be used as security for and to satisfy claims arising out of the transaction. On May 26, 2006, the parent delivered to the stockholder
representative for the sellers of the Company an indemnification claim against the escrow balance. A $12.4 million settlement was reached on May 30, 2007 by and between the Company and the sellers as part of a settlement
agreement that included a cash settlement to the Company paid out from the escrow account of $9 million and forfeiture of $3.4 million of unpaid tax benefits. Consistent with applicable accounting standards and SEC guidance, this transaction has
been accounted for as an adjustment to results of operations in the second quarter of 2007.

Operating Income. For the three and six
month periods ended June 30, 2007, operating income totaled $15.4 million and $17.9 million as compared to $2.9 million and $4.0 million in the same periods in 2006, primarily due to the May 2007 litigation settlement and improvement in gross
margin due to favorable product mix changes as previously discussed.

Interest expense for the three and six month periods ended
June 30, 2007 totaled $5.4 and $10.7 million as compared to $5.3 million and $10.3 million in the same periods in 2006. The increase in interest expense is a result of a $3.5 million increase in the amount of short-term debt outstanding
associated with the increased borrowing under the revolving line of credit facility during the fourth quarter of 2006, as compared to the same period in 2006.

Income Tax Benefit. Income tax expense for the three and six month periods ended June 30, 2007 differed from our normal effective tax rate, as the litigation settlement gain recognized during the second
quarter of 2007 is non-taxable. Excluding the impact of this non-taxable gain, the Companys effective tax rate remained consistent with the prior year. We expect to be able to utilize remaining tax benefits through the reversal of deferred tax
liabilities in future periods.



26



---

##### Table of Contents

Liquidity and Capital Resources

Operating activities provided $1.2 million of cash flow for the six month period ended June 30, 2007 compared to $6.6 million in the same period in 2006. Operating cash flow in the first six months of 2007
includes the impact of the litigation settlement. Excluding the impact of this settlement, cash provided by operating activities was approximately $14.4 million lower in 2007. The year-to-year change in operating cash flows activities reflects
(a) approximately $7.2 million associated with the receipt of income tax receivables in the 2006 period, (b) a decline in amounts payable to vendors as a result of increased payments in 2007, and (c) lower cash collections during the
first six months of 2006 resulting from staffing turnover within the accounts receivable department. The $9.0 million in cash received from the litigation settlement was used to fund payments to vendors, offset lower than anticipated cash
collections in the last month of the quarter and repayment, subsequent to quarter end, of $3.5 million of outstanding borrowings under the revolving credit facility. Days sales outstanding was 67 days for the six month period ended
June 30, 2007, remaining flat as compared to the same period in 2006; however, this was a one day reduction from the first quarter and a four day reduction from the fiscal year ended December 31, 2006.

During the six months ended June 30, 2007, cash collections totaled $170 million, as compared to $159 million in the same period in 2006. This 6.9%
increase is primarily a result of ongoing process improvements in our accounts receivable department.

Our cash balance decreased from $6.1
million at December 31, 2006 to $5.8 million at June 30, 2007. With the receipt of cash from the litigation settlement and the increase in cash collections during the six months ended June 30, 2007, the Company increased vendor
payments during the first six months of 2007 in response to a processing backlog that existed at the beginning of the year. Our days payable outstanding decreased in the first six months from 45 days as of December 31, 2006 to 34 days as
of June 30, 2007.

Investing activities used cash of $1.5 million in the six month period ended June 30, 2007 as compared to
$10.9 million for the same period in 2006. The first six months of 2006 includes proceeds from income tax refunds that were disbursed to former shareholders as required by the purchase agreement. Capital expenditures incurred in the six months ended
June 30, 2007 related to software development costs and computer equipment improvements. In the same period last year, these expenditures related primarily to ongoing capitalizable information technology projects and software improvements. The
Companys capital expenditure estimate for the remainder of 2007, which is subject to ongoing review and revisions, is approximately $2.4 million; such amount excludes an additional $1.9 million of expenditures expected to be incurred
associated with the Companys lease of new corporate office facilities. Occupation of this new leased facility is expected to occur during the third quarter of 2007.

There were no financing activities for the six months ended June 30, 2007 nor in the same period in 2006.

Our senior secured revolving credit facility consists of a $40 million revolving loan, subject to a borrowing base test. Based on the covenant levels under the senior secured revolving credit facility, we had, as of June 30, 2007, $6.9
million of available borrowing capacity under the revolving credit facility, a $4.0 million decrease from December 31, 2006, and had no additional borrowings on its revolving line of credit during the six month period ended June 30, 2007.
This decline in available borrowing capacity is due to the strong cash collections of eligible receivables during the first six months of 2007. See Recent Developments hereunder.

The senior secured revolving credit facility is guaranteed by the Parent, and secured by a first priority lien on substantially all of the Companys
and the Parents current and future assets, including all of the capital stock of MSC.

We believe that, based on current levels of
operations and anticipated growth, cash from operations, together with other available sources of liquidity, including borrowings available under our senior secured revolving credit facility, will be sufficient to fund operations, anticipated
capital expenditures and required payments on our debt for at least the next 12 months. In connection with our borrowings, net interest payments totaled $5.0 million in the six month



27



---

##### Table of Contents

period ended June 30, 2007. Our available sources of liquidity are dependent upon future operating performance,
which, in turn, is subject to factors beyond our control, including the conditions of the workers compensation industry. The Company cannot assure that its business will generate cash from operations, or that it will be able to obtain
financing from other sources, sufficient to satisfy its debt service or other requirements.

As of June 30, 2007, the Company was
compliant with all debt covenants.

Recent Developments

1. Subsequent eventOn July 23, 2007, the Company repaid $3.5 million of borrowings under the revolving credit facility, which reduced the outstanding short-term debt to $16.6 million.

2. The State of New York implemented pharmacy and durable goods workers compensation fee schedules, effective July 11, 2007, which
significantly reduced the maximum allowable reimbursements for pharmacy and ancillary workers compensation services in New York. We expect that there will be an adverse financial impact to operating results and cash flow over the short term.
We are working aggressively with our customers and vendors to mitigate the financial impact of this action.

Critical Accounting Estimates and Policies

There has been no change in the Companys Critical Accounting Estimates and Policies, as disclosed in the Annual Report on Form
10-K for the year ended December 31, 2006.

Item 3Quantitative and Qualitative Disclosures About Market Risk

Due to the significant amount of
indebtedness on our balance sheet, we are exposed to interest rate risk. Pursuant to the terms of our senior secured revolving credit facility, we are required to enter into interest rate swap contracts such that at least 50% of all of our and our
parents indebtedness is subject to fixed interest rate protection. Based on our current hedging positions, under which we have secured a fixed rate for over 50% of our indebtedness, and outstanding debt at June 30, 2007, a 1% increase in
interest rates would result in an increase in interest expense of $0.4 million.

Item 4TControls and Procedures

Managements Evaluation of the Companys Disclosure Controls and
Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Companys reports submitted under the Securities Exchange Act of 1934, as
amended (the Exchange Act), is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be
disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

The
Companys Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Companys management, have evaluated the effectiveness of the Companys disclosure controls and procedures (as such term is
defined in Rules 13a  15(e) and 15d  15(e) under the Exchange Act) and have concluded that the Companys disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this
report.

Changes in Internal Control Over Financial Reporting

There were no changes in the Companys internal control over financial reporting that occurred during the quarter ended June 30, 2007 that materially affected, or are reasonably likely to materially affect,
the Companys internal control over financial reporting.



28



---

##### Table of Contents

Part IIOther Information

Item 1Legal Proceedings

We are from time to time involved in litigation incidental to the conduct
of our business. We believe that no litigation currently pending against us, if adversely decided, would have a material adverse effect on our financial position or results of operations.

Item 1ARisk Factors

There have been no material changes to the risk factors previously disclosed
the Companys Annual Report on Form 10-K for the year ended December 31, 2006.

Item 2Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3Defaults upon Senior Securities

None

Item 4Submission of Matters to a Vote of Security Holders

None

Item 5Other Information

None

Item 6Exhibits

Pursuant to the terms of the Indenture dated as of June 21, 2005, among the
Registrant, MCP-MSC Acquisition, Inc. and U.S. Bank National Association relating to the Senior Secured Floating Rate Notes Due 2011, the Registrant is not required to provide the certifications contained in exhibits 31.1, 31.2, 32.1 and 32.2.



|            |  |                                                                                                                                                                                         
|----------- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                                                                                                             
|4.5         |  | Supplemental Indenture dated as of July 24, 2007 among MSCMedical Services Company, MSC Billing, Inc., MCPMSC Acquisition, Inc., and U.S. Bank National Association (the
Trustee). *
|10.26       |  | Amended and Restated Employment Agreement, dated July 16, 2007, by and between the Company and Gary S. Jensen. *                                                                        
|10.27       |  | Security Agreement Supplement dated as of July 24, 2007 between MSC Billing, Inc. and Bank of America, N.A., as administrative agent. *                                                 
|10.28       |  | Subsidiary Guaranty Supplement dated as of July 24, 2007 between MSC Billing, Inc. and Bank of America, N.A., as administrative agent. *                                                

---

|* | Previously filed
|- | ----------------



29



---

##### Table of Contents

SIGNATURES

Pursuant to the requirements of the Indenture dated as of June 21, 2005, among the Registrant,
MCP-MSC Acquisition, Inc. and U.S. Bank National Association relating to the Senior Secured Floating Rate Notes Due 2011, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



|                      |  |                              |  |                                                                                     
|--------------------- |  | ---------------------------- |  | ------------------------------------------------------------------------------------
|                      |  | MSCMedical Services Company
|                      |  |                             
|Date: August 14, 2007 |  | By:                          |  | /s/    JOSEPH P.
DELANEY                                                            
|                      |  |                              |  | Joseph P. Delaney                                                                   
|                      |  |                              |  | President and Chief Executive Officer                                               
|                      |  |                              |  | (principal executive officer)                                                       
|                      |  |                             
|Date: August 14, 2007 |  | By:                          |  | /s/    GARY S.
JENSEN                                                               
|                      |  |                              |  | Gary S. Jensen, Chief Financial Officer (principal financial and accounting officer)



30